Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia.

Trial Profile

Local Site Tolerability of Multiple Dose Treatment With Deltoid Intramuscular Injection of RISPERDAL CONSTA in Subjects With Chronic Schizophrenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2010

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 20 Mar 2010 Actual patient number (53) added as reported by ClinicalTrials.gov.
    • 30 Jan 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top